Zoryl 4 Tablet contains Glimepiride 4 mg, an oral hypoglycemic agent belonging to the sulfonylurea class, indicated for the management of type 2 diabetes mellitus. It functions by stimulating pancreatic beta cells to release insulin, thereby reducing blood glucose levels. Zoryl 4 is primarily prescribed for patients whose hyperglycemia cannot be controlled by diet and exercise alone. The medication is effective in improving glycemic control and may be used as monotherapy or in combination with other antidiabetic agents such as metformin or insulin. Glimepiride has a rapid onset of action and a prolonged duration, allowing once-daily dosing for improved patient compliance. It is essential to monitor blood glucose levels regularly during therapy to avoid hypoglycemia, a common adverse effect associated with sulfonylureas. Other potential side effects include weight gain, gastrointestinal disturbances, and allergic reactions. Zoryl 4 should be used cautiously in patients with hepatic or renal impairment, and contraindicated in individuals with type 1 diabetes, diabetic ketoacidosis, or known hypersensitivity to sulfonylureas. Patient education on diet, exercise, and recognition of hypoglycemia symptoms is crucial for optimal therapeutic outcomes. Always consult a healthcare professional before initiating or adjusting therapy with Zoryl 4 Tablet.